Journal
TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
Volume 10, Issue 6, Pages -Publisher
ASSOC RESEARCH VISION OPHTHALMOLOGY INC
DOI: 10.1167/tvst.10.6.21
Keywords
vascular permeability; vascular endothelial growth factor (VEGF); caveolin (Cav); peptides
Categories
Funding
- National Institutes of Health SBIR phase I grant
- Connecticut Innovations
Ask authors/readers for more resources
The study aimed to identify a novel CPP for improved delivery of a truncated Cav modulator. Results showed that fusion with peptide RRPPR efficiently blocked NO release and VEGF-induced permeability, reducing immune-mediated retinal damage.
Purpose: Caveolin (Cav) regulates various aspect of endothelial cell signaling and cell permeable peptides (CPPs) fused to domains of Cav can reduce retinal damage and inflammation in vivo. Thus, the goal of the present study was to identify a novel CPP that improves delivery of a truncated Cav modulator in vitro and in vivo. Methods: Phage display technology was used to identify a small peptide (RRPPR) that was internalized into endothelial cells. Fusions of Cav with the peptide were compared to existing molecules in three distinct assays, vascular endothelial growth factor-A (VEGF) induced nitric oxide (NO) release, VEGF induced vascular leakage, and in a model of immune mediated uveitis. Results: RRPPR was internalized efficiently and was potent in blocking NO release. Fusing RRPPR with a minimal Cav inhibitory domain (CVX51401) dose-dependently blocked NO release, VEGF induced permeability, and retinal damage in a model of uveitis. Conclusions: CVX51401 is a novel Cav modulator that reduces VEGF and immune mediated inflammation. Translational Relevance: CVX51401 is an optimized Cav modulator that reduces vascular permeability and ocular inflammation that is poised for clinical development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available